A new formulation allows mothers to stop bleeding

A new formulation of a drug to prevent excessive bleeding after childbirth could save thousands of women's lives in low- and middle-income countries, according to a study conducted by the World Health Organization (WHO) in collaboration with MSD for Mothers and Ferring Pharmaceuticals.

Currently, oxytocin is used as a first-line drug to prevent excessive bleeding after childbirth.

However, it must be kept and transported at 2 to 8 degrees Celsius, which is difficult to do in many countries, which prevents many women from having access to this vital medication.

And when they can get it, the drug may be less effective because of exposure to heat.

The study, published in the New England Journal of Medicine shows that thermostable carbetocin is a better alternative because it does not require refrigeration and retains its effectiveness for at least three years if stored at 30 degrees Celsius and 75 percent The clinical trial involved nearly 30,000 women who gave birth badlly in 10 countries: Kenya, Argentina, Egypt, India, Nigeria, Singapore, South Africa, Thailand, Uganda and the United Kingdom.

Each woman randomly received a single injection of thermostable carbetocin or oxytocin immediately after the birth of her baby.

Both drugs were also effective in preventing excessive bleeding after birth.

But because the two drugs were kept at the temperature In order to ensure maximum efficacy of oxytocin, the test could underestimate the expected benefit of the use of thermostable carbetocin in real conditions where oxytocin could be degraded due to exposure. "The development of a drug to prevent postpartum haemorrhage that remains effective in hot, humid conditions is very good news for millions of women who give birth in parts of the world without access to reliable refrigeration. said Dr. Metin Gülmezoglu, of the Department of Reproductive Health and Research at WHO

The next step is the regulatory review and approval by countries and the & # 39; WHO will ask its Development Group guidelines to consider thermostable carbetocin prevention of postpartum hemorrhage.

Postpartum haemorrhage is the leading direct cause of maternal death, accounting for 661,000 deaths worldwide between 2003 and 2009. In Kenya, it is the leading cause of maternal mortality, with 34% of deaths maternal. maternal deaths.

More than 70% of these deaths occur because of uterine atony, which results from poor contraction of the uterus after childbirth [19]. 659016] window.fbAsyncInit = function () {FB.init ({appId: "174023979648743", xfbml :! 0, version: "v2.5")}; (function (d, s, id) {var js, fjs = d.getElementsByTagName (s) [0]; if (d.getElementById (id)) {return} js = d.createElement (s); js.id = id; js.src = "http: // connect. facebook.net/en_US/sdk.js";fjs.parentNode.insertBefore(js,fjs)}(document,'script',&#39 ; facebook-jssdk & # 39;)) [ad_2]
Source link